Table 2.
Median Overall Survival (1-Year, Survival %) by Lines of Therapy and Surgical Resection/Biopsy
| All | No Cancer-Related Treatment | Radiation Alone | 1L+ | 2L+ | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (n = 3646) | (n = 748) | (n = 1032) | (N = 1866) | (N = 609) | ||||||
| R | B | R | B | R | B | R | B | R | B | |
| n = 2660 | n = 986 | n = 414 | n = 334 | n = 787 | n = 245 | n = 1496 | n = 370 | n = 530 | n = 79 | |
| Median follow-up time from diagnosis, mo | 7.4 | 3.6 | 2.6 | 2.1 | 5.0 | 3.7 | 11.9 | 5.4 | 18.0 | 13.4 |
| All patients | 5.9 (26) | 3.0 (8) | 2.0 (0) | 2.6 (3) | 3.6 (13) | 2.3 (4) | 8.8 (38) | 3.6 (16) | 8.0 (31) | 6.5 (22) |
| Tumor size (cm) | ||||||||||
| <5 | 6.5 (32)a | 3.6 (14)a | 2.8 (4)a | 2.3 (0)a | 3.7 (17)a | 2.5 (7.4) | 10.1 (43)a | 6.6 (25)a | 8.4 (35) | 8.1 (19) |
| 5-7 | 5.9 (26)a | 3.0 (7)a | 2.7 (4)a | 2.1 (0)a | 3.8 (13)a | 2.3 (3.5) | 8.6 (37)a | 3.2 (14)a | 7.9 (30) | 6.3 (26) |
| >7 | 3.8 (13)a | 2.2 (4)a | 2.0 (0)a | 1.6 (0)a | 2.7 (4)a | 1.9 (0) | 6.0 (26)a | 2.5 (6)a | 6.0 (25) | 1.7 (0) |
| Age, y | ||||||||||
| 66-70 | 8.1 (36)a | 3.1 (11)a | 2.7 (7) | 1.8 (0) | 4.7 (19)a | 3.1 (5)a | 10.3 (44)a | 3.8 (21) | 8.1 (32) | 6.9 (28) |
| 71-75 | 6.4 (27)a | 3.4 (8)a | 2.7 (5) | 2.3 (0) | 4.3 (18)a | 2.9 (7)a | 8.4 (36)a | 3.9 (13) | 8.0 (30) | 6.2 (19) |
| 76-80 | 5.0 (21)a | 3.1 (11)a | 2.6 (0) | 2.0 (0) | 3.2 (10)a | 2.2 (1)a | 7.0 (32)a | 3.9 (23) | 7.3 (29) | 7.6 (21) |
| ≥80 | 4.0 (13)a | 2.8 (4)a | 2.5 (0) | 2.0 (0) | 2.6 (5)a | 2.0 (3)a | 6.6 (31)a | 3.2 (10) | 8.5 (38) | 6.5 (14) |
| CCI | ||||||||||
| 0 | 6.8 (31)a | 3.2 (10) | 2.7 (4) | 2.1 (0) | 4.2 (15)a | 2.8 (5) | 10.1 (43)a | 3.6 (19) | 7.8 (30) | 8.2 (29)a |
| 1 | 5.9 (25)a | 2.8 (6) | 2.5 (0) | 2.1 (0) | 3.4 (13)a | 1.9 (1) | 8.1 (34)a | 3.0 (14) | 8.5 (35) | 3.9 (0)a |
| ≥2 | 4.2 (17)a | 3.1 (6) | 2.4 (4) | 2.0 (0) | 2.7 (9)a | 2.0 (4) | 6.4 (26)a | 4.9 (14) | 7.6 (27) | 4.5 (21)a |
Abbreviations: R, surgical resection; B, biopsy only; CCI, Charlson Comorbidity Index; 1L+, received first line of systemic therapy; 2L+, received second line of systemic therapy. Time starts from diagnosis date from the untreated and from the start of the line in the treated (1L+ starts from start of first line; 2L+ starts from start of second line).
aStatistical significance (P < .05) among categories of tumor size, age, and CCI.